Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies for Multiple Myeloma — What Clinicians Want To Know

Faculty

Meletios-Athanasios (Thanos) C Dimopoulos

MD

National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

Professor and Chairman, Plasma Cell Dyscrasias Unit, Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine

Faculty

Suzanne Trudel

MD

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

PM Clinician Scientist, Associate Professor

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

Additional faculty to be announced.

Join us on Friday, December 11^th from 3:15 PM to 5:15 PM central time (4:15 PM to 6:15 PM eastern time).

MODULE 1: Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)

MODULE 2: Ocular Toxicities and Other Tolerability Considerations with ADCs for MM

MODULE 3: Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for MM to facilitate their integration into current management algorithms.
• Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
• Implement a plan of care to recognize and manage the toxicities associated with bispecific antibodies and ADCs commonly used for MM in order to maintain patient quality of life and time on treatment.
• Assess available research data with BCMA-directed bispecific antibodies for patients with relapsed/refractory (R/R) MM, and appreciate the clinical role of these agents.
• Recall recently presented clinical trial results establishing the definitive efficacy of BCMA-directed bispecific antibody therapy in combination with anti-CD38 monoclonal antibody therapy for patients with R/R MM, and integrate this novel therapeutic strategy into current management algorithms.
• Recall available data with novel bispecific antibody- and ADC-based strategies currently under investigation for MM, and appropriately discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
To be announced.

MODERATOR
To be announced.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.